News

The partnership will initially focus on low-abundance biomarkers supporting translational research in Alzheimer's disease.
Acumen and JCR aim to develop a product leveraging Acumen's amyloid beta oligomer-selective antibody expertise and JCR's transferrin-receptor-targeting blood-brain barrier-penetrating technologyPrecli ...
Eli Lilly and Company (NYSE: LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...
Days after JCR Pharmaceuticals signed a deal with AstraZeneca’s rare disease unit, the Japanese biopharma has secured a ...
Robert Johnson was last seen on Monday night at an apartment complex on Trinity Place, and police are hoping someone knows ...
Fiona Phillips ’ husband Martin Frizell has opened up about the painful moment the TV presenter failed to recognise their ...
A groundbreaking study reveals that misfolded "stealth" proteins—not just plaques—may play a major role in cognitive decline.
Connecticut joins more than 20 states mandating insurance coverage cover biomarker tests, said Christy Kovel, director of ...
DAYTON — The Alzheimer’s Association Northwest Ohio Chapter is hosting several free programs in July. Register for these and ...
New research shows that signs of Alzheimer’s disease can already be detected in the blood of people as young as their 40s.
The eye test would be another tool for early diagnosis of degenerative brain diseases. A blood test that assists with early ...
A Finnish population study shows that signs related to Alzheimer's disease may already be found in the brain in middle age.